Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Androxal in Secondary Hypogonadism (ZA-302)
NCT01739595Phase 3Completed
- Sponsor
- Repros Therapeutics Inc.
- Start
- Nov 2012
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enclomiphene in secondary hypogonadism (HH), sponsored by Repros Therapeutics Inc.. Started Nov 2012; status: completed.
02
Drugs
enclomiphene
03
Conditions
secondary hypogonadism (HH)
Beyond the preview
Go deeper on NCT01739595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01739595.